A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy. Earnings for ViewRay are expected to grow in the coming year, from ($0.60) to ($0.49) per share. MarketBeat has tracked 6 news articles for ViewRay this week, compared to 2 articles on an average week. ViewRay does not have a long track record of dividend growth.

In the next year, analysts predict that Fair Value will reach $3.58 – an increase of 100.00%. For the next nine years, the forecast is for Fair Value to grow by 100.00%. The average analyst rating for ViewRay stock from 14 stock analysts is “Buy”. This means that analysts believe this stock is likely to outperform the market over the next twelve months. ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System.

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company’s employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

ViewRay Stock Forecast, Price Target & Prediction (VRAY)

Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.

Over the next nine years, experts predict that EBIT will grow by 3.55%. In the last two years, ViewRay’s Net Income has gone down from $-120.20M to $-110.05M – a 8.44% drop. For next year, the 0 analysts predict Net Income of $-112.80M, which would mean an increase of 2.50%. Over the next nine years, the pros’ prediction is Net Incomeof $-112.60M, which would mean a nine-year growth forecast of 2.32%. The average price target estimation represents a 76.55% change from ViewRay’s last price ($3.54).

Growth & Valuation

The ABR is the calculated average of the actual recommendations made by the brokerage firms for a given stock. ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging system. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH. In the last two years, ViewRay’s EBIT has decreased by 8.19%, going from $-112.90M to $-103.65M. For the next year, analysts are expecting EBIT to reach $-107.46M – an increase of 3.68%.

Information is provided ‘as-is’ and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data. According to undefined Wall Street analysts, ViewRay’s projected average annual EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. ViewRay’s average quarter SG&A projection for Dec 22 is $21.92M, based on 18 Wall Street analysts, with a range of $17.53M to $26.30M. The forecast indicates a 8.12% rise compared to VRAY last annual SG&A of $20.27M .

VRAY FAQ

However, it can guide investors looking to buy or sell a stock. On average, Wall Street analysts predict that Viewray’s share price could reach $7.00 by Feb 28, 2024. The average Viewray stock price prediction forecasts a potential upside of 97.74% from the current VRAY share price of $3.54. StockForecast enables investors to make better investment decisions by providing financial data and objective market analysis. StockForecast has the objective information you need to analyze stocks and currencies. StockForecast is not a personal financial advisor and does not make recommendations or offers to buy or sell securities or currencies.

• Top institutional investors include Artisan Partners Limited Partnership (9.19%), Neuberger Berman Group LLC (5.44%), Group One Trading L.P.
• ViewRay had total cash and cash equivalents of $142.5M at December 31,…
• In the last two years, ViewRay’s EBITDA has decreased from $-108.20M to $-97.56M – a 9.83% drop.
• These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts.
• Based on 8 analysts giving stock ratings to VRAY in the past 3 months.

StockInvest.us is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon StockInvest.us. By using the site you agree and are held liable for your own investment decisions and agree to the Terms of Use and Privacy Policy.Please read the full disclaimer here.

Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. understanding currency pairs correlation for forex trading 2020 The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

5 Wall Street research analysts have issued 1 year price targets for ViewRay’s shares. On average, they expect the company’s stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 90.7% from the stock’s current price.

ViewRay Stock Forecast for 2027

Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, Scott William Drake, Susan C Schnabel and Zachary William Stassen. Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of ViewRay is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short interest in ViewRay has recently increased by 1.52%, indicating that investor sentiment is decreasing.

ViewRay currently has an average brokerage recommendation of 1.29 on a scale of 1 to 5 , calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations. ViewRay’s average annual SG&A projection for Dec 22 is $78.84M, based on 19 Wall Street analysts, with a range of $63.07M to $94.61M. The forecast indicates a 9.30% rise compared to VRAY last annual SG&A of $72.14M .

ViewRay’s average quarter revenue forecast for Dec 22 based on 18 analysts is $22.00M, with a low forecast of $17.60M, and a high forecast of $26.40M. VRAY’s average quarter revenue forecast represents a -16.95% decrease compared to the company’s last quarter revenue of $26.49M . ViewRay’s average annual revenue forecast for Dec 22 based on 19 analysts is $71.47M, with a low forecast of $57.17M, and a high forecast of $85.76M. VRAY’s average annual revenue forecast represents a 1.92% increase compared to the company’s last annual revenue of $70.12M . According to 14 stock analysts, the average 12-month stock price forecast for ViewRay stock is $7.27, which predicts an increase of 105.95%. There are few to no technical positive signals at the moment.

ViewRay Inc (NASDAQ:VRAY)

VRAY’s average annual net income forecast represents a NaN% decrease compared to the company’s last annual net income of $NaN . Undefined analysts predict VRAY’s average quarter Ebitda for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ViewRay’s previous annual Ebitda of $NaN. In 2025, VRAY is forecast to generate $38,033,677,337 in revenue, with the lowest revenue forecast at $38,033,677,337 and the highest revenue forecast at $38,033,677,337. On average, 4 Wall Street analysts forecast VRAY’s earnings for 2024 to be -$70,904,083, with the lowest VRAY earnings forecast at -$89,084,617, and the highest VRAY earnings forecast at -$50,905,495. The stock has broken the wide and falling short-term trend down.

These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month.

View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for ViewRay in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” VRAY shares.

In 2022, ViewRay’s revenue was $102.21 million, an increase of 45.76% compared to the previous year’s $70.12 million. There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viewray (VRAY – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments. With a 7.85% short float and 5.25 days to cover I would expect a large spike in the next few days to finish off this pattern.

ViewRay sees FY23 sees total revenue increase of 25%-40% For FY23, ViewRay anticipates total revenue will increase 25%-40% and adjusted EBITDA in the range of ($70M)-($80M). This info isn’t a recommendation for what you should personally do, so please don’t take the data as investment advice. With no support below and resistance from accumulated volume @ $3.62, some $0.0800 (2.26%) from the current price of $3.54, our system finds the risk reward not very attractive. Prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherap… Study’s primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART DENVER , Oct. 24, 2022 /PR…

ViewRay’s Revenue has decreased In the last two years, from $87.78M to $70.12M – a 20.12% drop. In the next year, analysts predict https://day-trading.info/ that Revenue will reach $74.00M – an increase of 5.53%. For the next nine years, the forecast is for Revenue to grow by 4.82%.

In the past three months, ViewRay insiders have not sold or bought any company stock. Only 4 people have searched for VRAY on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

4.79% of the outstanding shares of ViewRay have been sold short. ViewRay has only been the subject of 1 research reports in the past 90 days. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations.